Literature DB >> 16113045

Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy.

D S Rampton1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16113045      PMCID： PMC1774683          DOI： 10.1136/gut.2005.076034

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  11 in total

Review 1.  Infliximab in the treatment of Crohn's disease: a user's guide for clinicians.

Authors:  William J Sandborn; Stephen B Hanauer
Journal:  Am J Gastroenterol       Date:  2002-12       Impact factor: 10.864

2.  High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy.

Authors:  William S Mow; Maria T Abreu-Martin; Konstantinos A Papadakis; Howard E Pitchon; Stephan R Targan; Eric A Vasiliauskas
Journal:  Clin Gastroenterol Hepatol       Date:  2004-04       Impact factor: 11.382

3.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

4.  Tuberculosis at the end of the 20th century in England and Wales: results of a national survey in 1998.

Authors:  A M Rose; J M Watson; C Graham; A J Nunn; F Drobniewski; L P Ormerod; J H Darbyshire; J Leese
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

5.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study.

Authors:  Gunnar Järnerot; Erik Hertervig; Ingalill Friis-Liby; Lars Blomquist; Per Karlén; Christer Grännö; Mogens Vilien; Magnus Ström; Ake Danielsson; Hans Verbaan; Per M Hellström; Anders Magnuson; Bengt Curman
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

Review 6.  Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

Authors:  Michael A Gardam; Edward C Keystone; Richard Menzies; Steven Manners; Emil Skamene; Richard Long; Donald C Vinh
Journal:  Lancet Infect Dis       Date:  2003-03       Impact factor: 25.071

Review 7.  Infliximab treatment of rheumatoid arthritis.

Authors:  Sir Ravinder Maini
Journal:  Rheum Dis Clin North Am       Date:  2004-05       Impact factor: 2.670

8.  Granulomatous infectious diseases associated with tumor necrosis factor antagonists.

Authors:  R S Wallis; M S Broder; J Y Wong; M E Hanson; D O Beenhouwer
Journal:  Clin Infect Dis       Date:  2004-04-15       Impact factor: 9.079

9.  Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report.

Authors:  Juan J Gómez-Reino; Loreto Carmona; Vicente Rodríguez Valverde; Emilio Martín Mola; Maria Dolores Montero
Journal:  Arthritis Rheum       Date:  2003-08

Review 10.  Optimizing anti-TNF treatment in inflammatory bowel disease.

Authors:  Paul Rutgeerts; Gert Van Assche; Séverine Vermeire
Journal:  Gastroenterology       Date:  2004-05       Impact factor: 22.682
View more
  6 in total

Review 1.  Advances in therapeutic approaches to ulcerative colitis and Crohn's disease.

Authors:  Simon Travis
Journal:  Curr Gastroenterol Rep       Date:  2005-12

2.  European evidence based consensus on the diagnosis and management of Crohn's disease: current management.

Authors:  S P L Travis; E F Stange; M Lémann; T Oresland; Y Chowers; A Forbes; G D'Haens; G Kitis; A Cortot; C Prantera; P Marteau; J-F Colombel; P Gionchetti; Y Bouhnik; E Tiret; J Kroesen; M Starlinger; N J Mortensen
Journal:  Gut       Date:  2006-03       Impact factor: 23.059

Review 3.  Medical management of Crohn's disease.

Authors:  J R Fraser Cummings; Satish Keshav; Simon P L Travis
Journal:  BMJ       Date:  2008-05-10

Review 4.  Current and emerging drugs for the treatment of inflammatory bowel disease.

Authors:  John K Triantafillidis; Emmanuel Merikas; Filippos Georgopoulos
Journal:  Drug Des Devel Ther       Date:  2011-04-06       Impact factor: 4.162

Review 5.  Core indicators of an evaluation and guidance system for quality of care in inflammatory bowel disease centers: A critical review.

Authors:  Yueying Chen; Jun Shen
Journal:  EClinicalMedicine       Date:  2022-04-07

6.  Incidence of Active Tuberculosis within One Year after Tumor Necrosis Factor Inhibitor Treatment according to Latent Tuberculosis Infection Status in Patients with Inflammatory Bowel Disease.

Authors:  Jieun Kang; Dae Hyun Jeong; Minkyu Han; Suk-Kyun Yang; Jeong-Sik Byeon; Byong Duk Ye; Sang Hyoung Park; Sung Wook Hwang; Tae Sun Shim; Kyung-Wook Jo
Journal:  J Korean Med Sci       Date:  2018-10-23       Impact factor: 2.153
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.